The market expects Ovid Therapeutics (OVID) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if t ...

The market expects On Holding (ONON) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on May 13, 2025, might help the stock move higher if these key numbers are bette ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Vivos Therapeutics, Inc. (VVOS) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the ...

Company Overview - Fox Corporation is expected to report quarterly earnings of $0.96 per share, reflecting a year-over-year decline of 11.9% [3] - Revenues are anticipated to reach $4.15 billion, which is an increase of 20.5% compared to the same quarter last year [3] Earnings Expectations - The consensus EPS estimate has been revised 4.84% higher in the last 30 days, indicating a positive reassessment by analysts [4] - The Most Accurate Estimate for Fox is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +4.53% [10][11] - Fox currently holds a Zacks Rank of 2 (Buy), suggesting a strong likelihood of beating the consensus EPS estimate [11] Historical Performance - In the last reported quarter, Fox exceeded the expected earnings of $0.61 per share by delivering $0.96, resulting in a surprise of +57.38% [12] - Over the past four quarters, Fox has beaten consensus EPS estimates three times [13] Industry Context - E.W. Scripps, another player in the Zacks Broadcast Radio and Television industry, is expected to report a loss of $0.23 per share, indicating a year-over-year change of -130% [17] - E.W. Scripps has an Earnings ESP of 0.00% and has not beaten consensus EPS estimates in any of the last four quarters [18]

Core Viewpoint - The market anticipates a year-over-year decline in earnings for Arcturus Therapeutics despite an increase in revenues, with the actual results being crucial for stock price movement [1][2]. Earnings Expectations - Arcturus Therapeutics is expected to report a quarterly loss of $1.13 per share, reflecting a year-over-year change of -13% [3]. - Revenues are projected to be $38.08 million, which is a slight increase of 0.2% from the previous year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 5% over the last 30 days, indicating a bearish sentiment among analysts [4]. - The Most Accurate Estimate for Arcturus is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -9.49% [10][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from the consensus estimate, with a strong predictive power for positive readings [6][7]. - Stocks with a positive Earnings ESP and a Zacks Rank of 1, 2, or 3 have historically shown a nearly 70% chance of a positive surprise [8]. Historical Performance - In the last reported quarter, Arcturus was expected to post a loss of $0.34 per share but instead reported a loss of $1.11, resulting in a surprise of -226.47% [12]. - Over the past four quarters, Arcturus has beaten consensus EPS estimates three times [13]. Conclusion - Arcturus Therapeutics does not appear to be a strong candidate for an earnings beat based on current estimates and rankings, suggesting caution for investors [16].

Core Viewpoint - Regenxbio (RGNX) is anticipated to report a significant year-over-year increase in earnings and revenues for the quarter ended March 2025, which could influence its stock price depending on the actual results compared to estimates [1][2]. Earnings Expectations - The upcoming earnings report is expected to be released on May 12, 2025, with a consensus estimate of $0.41 per share, reflecting a year-over-year increase of +129.7% [3]. - Revenues are projected to reach $109.98 million, representing a substantial increase of 604.1% from the same quarter last year [3]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised down by 6.26%, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Regenxbio is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +57.77% [10][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive Earnings ESP reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [8]. - Regenxbio currently holds a Zacks Rank of 3, indicating a likelihood of beating the consensus EPS estimate [11]. Historical Performance - In the last reported quarter, Regenxbio was expected to post a loss of $1.27 per share but actually reported a loss of $1.01, resulting in a surprise of +20.47% [12]. - Over the past four quarters, the company has surpassed consensus EPS estimates two times [13]. Industry Context - In the Zacks Medical - Biomedical and Genetics industry, Sangamo Therapeutics (SGMO) is expected to report a loss of $0.11 per share for the same quarter, with a year-over-year change of +59.3% [17]. - Sangamo's revenue is projected to be $9.17 million, up 1810.4% from the previous year [17]. - Despite a recent downward revision of 23.8% in consensus EPS estimates, Sangamo has an Earnings ESP of 27.27%, but it holds a Zacks Rank of 4 (Sell), making predictions of an earnings beat uncertain [18].

Core Viewpoint - Opus Genetics, Inc. is anticipated to report a year-over-year decline in earnings despite an increase in revenues for the quarter ending March 2025, with the consensus outlook indicating a significant impact on the stock price based on actual results compared to estimates [1][3]. Financial Performance Expectations - The company is expected to post a quarterly loss of $0.34 per share, reflecting a year-over-year change of -17.2% [3]. - Revenues are projected to be $2.8 million, which represents a 63.7% increase from the same quarter last year [3]. Estimate Revisions and Predictions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4]. - The Most Accurate Estimate aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0%, suggesting no recent differing analyst views [10]. Earnings Surprise History - In the last reported quarter, the company was expected to post a loss of $0.34 per share but instead reported a loss of $1.27, resulting in a surprise of -273.53% [12]. - Over the past four quarters, Opus Genetics has only beaten consensus EPS estimates once [13]. Industry Comparison - Cue Biopharma, another player in the Zacks Medical - Biomedical and Genetics industry, is expected to report a loss of $0.14 per share for the same quarter, indicating a year-over-year change of +44% [17]. - Cue Biopharma's revenues are expected to be $2 million, up 16.3% from the previous year, with an unchanged consensus EPS estimate over the last 30 days [17][18].

Company Overview - Veren (VRN) is expected to report a year-over-year increase in earnings of +31.8% to $0.29 per share, despite a revenue decline of 12.4% to $719.9 million for the quarter ended March 2025 [3][12] - The stock's price movement will largely depend on how actual results compare to consensus estimates, with a potential for higher stock prices if results exceed expectations [1][2] Earnings Estimates and Revisions - The consensus EPS estimate for Veren has been revised 25% higher in the last 30 days, indicating a bullish sentiment among analysts [4] - The Most Accurate Estimate for Veren is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +13.79%, suggesting a strong likelihood of beating the consensus EPS estimate [10][11] Earnings Surprise History - In the last reported quarter, Veren exceeded expectations by delivering earnings of $0.29 per share against an expected $0.24, resulting in a surprise of +20.83% [12] - Over the last four quarters, Veren has beaten consensus EPS estimates only once, indicating a mixed performance history [13] Industry Context - In the Zacks Oil and Gas - Integrated - Canadian industry, Cenovus Energy (CVE) is expected to report earnings of $0.29 per share, reflecting a year-over-year decline of -37%, with revenues projected at $9.55 billion, down 3.9% [17] - Cenovus has seen a 1.6% downward revision in its consensus EPS estimate over the last 30 days, and its Earnings ESP is currently at 0.00%, making it difficult to predict a beat against consensus estimates [18]

Core Viewpoint - The market anticipates Costamare (CMRE) will report a year-over-year decline in earnings due to lower revenues for the quarter ended March 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - Costamare is expected to post quarterly earnings of $0.52 per share, reflecting a year-over-year decrease of 17.5% [3]. - Revenues are projected to be $412.67 million, down 13.2% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 17% higher in the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Costamare is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +6.80% [10][11]. Earnings Surprise Prediction - A positive Earnings ESP reading suggests a potential earnings beat, especially when combined with a strong Zacks Rank [8]. - However, Costamare currently holds a Zacks Rank of 4, complicating the prediction of an earnings beat despite the positive Earnings ESP [11]. Historical Performance - In the last reported quarter, Costamare exceeded the expected earnings of $0.66 per share by delivering $0.69, resulting in a surprise of +4.55% [12]. - The company has beaten consensus EPS estimates in each of the last four quarters [13]. Industry Context - In the Zacks Transportation - Shipping industry, Ardmore Shipping (ASC) is expected to report earnings of $0.15 per share, indicating a year-over-year decline of 83.7% [17]. - Ardmore Shipping's consensus EPS estimate has been revised 37.8% lower in the last 30 days, leading to an Earnings ESP of -10.35% [18].

Core Viewpoint - The market anticipates Cheniere Energy (LNG) will report a year-over-year increase in earnings driven by higher revenues when it releases its quarterly results for the period ending March 2025 [1] Earnings Expectations - Cheniere Energy is expected to report quarterly earnings of $2.81 per share, reflecting a year-over-year increase of +31.9% [3] - Revenues are projected to be $4.47 billion, which is a 5.2% increase from the same quarter last year [3] Estimate Revisions - The consensus EPS estimate has been revised down by 9.73% over the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for Cheniere Energy matches the Zacks Consensus Estimate, resulting in an Earnings ESP of 0% [10][11] Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from the consensus estimate, with a strong predictor for positive readings [7][8] - Cheniere Energy's current Zacks Rank is 3 (Hold), making it challenging to predict an earnings beat conclusively [11] Historical Performance - In the last reported quarter, Cheniere Energy was expected to post earnings of $2.69 per share but delivered $4.33, resulting in a surprise of +60.97% [12] - Over the past four quarters, the company has beaten consensus EPS estimates three times [13] Industry Comparison - Civitas Resources (CIVI), another player in the Oil and Gas - Exploration and Production sector, is expected to report earnings of $1.68 per share for the same quarter, indicating a year-over-year decline of -3.5% [17] - Civitas has seen a 24.4% downward revision in its consensus EPS estimate over the last 30 days, but a higher Most Accurate Estimate has resulted in an Earnings ESP of 0.17% [18]